Key Takeaways
- • Artemis Capital Partners closes Fund IV with $254 million in capital commitments from existing and new limited partners, marking the firm's fourth institutional fund.
- • The fund targets small manufacturers of specialized technical products including sensors, test and measurement instruments, RF and microwave components, optics, and advanced materials, with sectors of interest spanning analytical instruments, thermal management, and diagnostics.
- • Fund IV has already deployed capital across three platform company investments in industrial technology serving aerospace, defense, life science, and semiconductor customers.
- • Recent exits demonstrate the firm's operational track record: April 2026 sale of Sightline Intelligence to Acron Technologies (TJC portfolio company), October 2025 Taiwan-based acquisition of Tekscan by Uneo, and 2021 sale of BioDot for $84 million to ATS.
- • CEO James Ward and CIO Euan Milne highlighted investor confidence in the firm's team execution and platform-building strategy focused on add-on acquisition rollups.
Summary
Artemis Capital Partners has successfully closed its fourth institutional fund at $254 million in committed capital, securing backing from both existing limited partners and new investors. The fund close reflects sustained institutional confidence in Artemis' investment thesis and operational execution within the specialized industrial technology sector.
Artemis pursues a platform-and-bolt-on acquisition strategy, targeting small-to-mid-market manufacturers of technically differentiated products. The firm's investment scope spans sensors, test and measurement instruments, radio-frequency and microwave components, optics, advanced materials, analytical instruments, thermal management systems, and diagnostics platforms. Fund IV's explicit sector focus includes companies serving aerospace, defense, life science, and semiconductor end markets—defensive, high-specification verticals with structural demand drivers.
The firm has demonstrated its ability to execute exits and return capital to investors, a critical factor in fundraising momentum. In April 2026, Artemis sold Sightline Intelligence, an Oregon-based developer of onboard video processing systems for unmanned aircraft, vehicles, and vessels, to Acron Technologies (a portfolio company of TJC). Additionally, in October 2025, Taiwan-based Uneo acquired Tekscan, a pressure-measurement sensor manufacturer. A prior exit included the 2021 sale of BioDot, a fluid-dispensing equipment manufacturer, to ATS for $84 million. These realizations validate the firm's platform-building and value-creation methodology.
Fund IV has already begun capital deployment, with three platform company investments completed. CEO James Ward and CIO Euan Milne both emphasized investor conviction in the team's strategy and execution track record. The successful close positions Artemis to continue its niche-focused consolidation strategy within technical manufacturing, where operational scale and add-on acquisition capabilities drive returns.
Artemis pursues a platform-and-bolt-on acquisition strategy, targeting small-to-mid-market manufacturers of technically differentiated products. The firm's investment scope spans sensors, test and measurement instruments, radio-frequency and microwave components, optics, advanced materials, analytical instruments, thermal management systems, and diagnostics platforms. Fund IV's explicit sector focus includes companies serving aerospace, defense, life science, and semiconductor end markets—defensive, high-specification verticals with structural demand drivers.
The firm has demonstrated its ability to execute exits and return capital to investors, a critical factor in fundraising momentum. In April 2026, Artemis sold Sightline Intelligence, an Oregon-based developer of onboard video processing systems for unmanned aircraft, vehicles, and vessels, to Acron Technologies (a portfolio company of TJC). Additionally, in October 2025, Taiwan-based Uneo acquired Tekscan, a pressure-measurement sensor manufacturer. A prior exit included the 2021 sale of BioDot, a fluid-dispensing equipment manufacturer, to ATS for $84 million. These realizations validate the firm's platform-building and value-creation methodology.
Fund IV has already begun capital deployment, with three platform company investments completed. CEO James Ward and CIO Euan Milne both emphasized investor conviction in the team's strategy and execution track record. The successful close positions Artemis to continue its niche-focused consolidation strategy within technical manufacturing, where operational scale and add-on acquisition capabilities drive returns.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.